PACT Pharma, a SouthSan Francisco, Calif.-based advancing personalized NeoTCR-T cell therapies to eradicate solid tumors, closed a $75m Series C financing
South San Francisco-based PACT Pharma, a provider of personalized cell therapy for solid tumors, has appointed Tim Moore as president and chief technical officer. Previously, Moore worked at Kite where he was executive vice president of technical operations. PACT Pharma's backers included GV, Canaan, Casdin Capital, Droia, Foresite Capital, Invus, Pontifax, Wu Capital, AbbVie Ventures and Taiho Ventures.